Table 3.
PS-weighted Cox analysis of transplant outcomes, adjusted for kind of conditioning and stem cell source
| Type of transplant | NRM | RI | LFS | OS | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95 % CI | p | HR | 95 % CI | p | HR | 95 % CI | p | HR | 95 % CI | p | |
| Global population | ||||||||||||
| Auto-HSCT (reference) | 1 | 1 | 1 | 1 | ||||||||
| 10/10 UD-HSCT | 3.1 | 2–4.7 | <10−5 | 0.5 | 0.4–0.7 | <10−5 | 0.7 | 0.6–0.9 | 0.0016 | 0.97 | 0.8–1.2 | 0.84 |
| 9/10 UD-HSCT | 4.5 | 2.5–8.1 | <10−5 | 0.5 | 0.3–0.8 | 0.0016 | 0.8 | 0.6–1.1 | 0.227 | 1.1 | 0.8–1.7 | 0.49 |
| By cytogenetic risk | ||||||||||||
| Good risk | ||||||||||||
| Auto-HSCT (reference) | 1 | 1 | 1 | 1 | ||||||||
| 10/10 UD-HSCT | 1.9 | 0.7–5.5 | 0.24 | 0.5 | 0.3–0.9 | 0.018 | 0.7 | 0.4–1.1 | 0.1 | 1.1 | 0.6–2 | 0.7 |
| Intermediate risk | ||||||||||||
| Auto-HSCT (reference) | 1 | 1 | ||||||||||
| 10/10 UD-HSCT | 3.6 | 2–6.4 | <10−4 | 0.5 | 0.4–0.7 | <10−5 | 0.7 | 0.6–0.9 | 0.01 | 0.98 | 0.7–1.3 | 0.9 |
| 9/10 UD-HSCT | 9.4 | 4.9–18 | <10−5 | 0.4 | 0.3–0.8 | 0.004 | 1.1 | 0.7–1.6 | 0.7 | 1.6 | 1.001–2.5 | 0.049 |
| Intermediate wtFLT3 | ||||||||||||
| Auto-HSCT (reference) | 1 | 1 | 1 | 1 | ||||||||
| 10/10 UD-HSCT | 2.8 | 0.8–9.8 | 0.11 | 0.5 | 0.29–0.98 | 0.04 | 0.6 | 0.4–1.1 | 0.10 | 0.95 | 0.53–1.7 | 0.88 |
| Poor risk | ||||||||||||
| Auto-HSCT (reference) | 1 | 1 | 1 | 1 | ||||||||
| 10/10 UD-HSCT | 6.3 | 2.3–17.4 | 0.0004 | 0.5 | 0.3–0.7 | 0.0003 | 0.7 | 2.3–17.4 | 0.0004 | 0.9 | 0.6–1.2 | 0.4 |
| 9/10 UD-HSCT | 11.7 | 4–34.7 | <10−5 | 0.7 | 0.4–1 | 0.08 | 1.03 | 0.7–1.5 | 0.88 | 1.3 | 0.9–1.9 | 0.2 |
Legend: wtFLT3 wild-type FLT3